MORAb-004 is a monoclonal antibody that binds to endosialin/tumor endothelial marker-1 (TEM-1). The randomized, double-blind study is designed to assess the efficacy and safety of single agent MORAb-004
In pursuance of the memorandum of understanding signed with the Government of Gujarat in 2009, the company had invested over Rs5bn ($100m) to build a SEZ. Jubilant Life
Addressing the problems faced by the small scale industry (SSI) sector, the MP Pharmaceutical Manufacturers Association, supported by IPA, is planning to submit a mass representation to the
The Addplan 6.0 PE provides the statistical methodology, simulation and analysis tools for adaptive clinical trials that include an enrichment design. The adaptive trial software will be of
The company now offers Megavitamin No 1 Pack, which provides a 28-day supply of all the essential vitamins, minerals, extra herbs, nutrients and amino acids. Another new product
DFH will work with the NIAID’s Division of AIDS (DAIDS) under a material evaluation agreement that will allow for the pre-clinical assessment of the promising maturation inhibitor compounds.
The Afirma Thyroid FNA Analysis combines cytopathology assessment of thyroid nodule fine needle aspiration (FNA) samples with the Afirma Gene Expression Classifier for improved thyroid nodule diagnosis. The
LunaRich is a whole soy powder containing five to ten times more lunasin, a peptide found naturally in soy than the industry standard. Previous studies demonstrated that lunasin
The platform delivers data management, organization and subsequent connection with downstream development, while supporting regulatory compliance and protecting intellectual property. It incorporates the ability to search across experiments,
As per the agreement, Vanda will pay an initial license fee of $1m to Eli Lilly and will be responsible for all development costs. Lilly is also eligible
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.